BIVRX vs. QLEIX
Compare and contrast key facts about Invenomic Fund (BIVRX) and AQR Long-Short Equity Fund (QLEIX).
BIVRX is managed by Invenomic. It was launched on Jun 18, 2017. QLEIX is managed by AQR Funds. It was launched on Jul 15, 2013.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIVRX or QLEIX.
Key characteristics
| BIVRX | QLEIX | |
|---|---|---|
| YTD Return | -6.57% | 18.19% |
| 1Y Return | -3.14% | 40.67% |
| 3Y Return (Ann) | 19.81% | 21.26% |
| 5Y Return (Ann) | 24.86% | 15.28% |
| Sharpe Ratio | -0.11 | 1.51 |
| Daily Std Dev | 28.36% | 27.11% |
| Max Drawdown | -25.39% | -39.20% |
| Current Drawdown | -22.20% | -2.76% |
Correlation
The correlation between BIVRX and QLEIX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BIVRX vs. QLEIX - Performance Comparison
In the year-to-date period, BIVRX achieves a -6.57% return, which is significantly lower than QLEIX's 18.19% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIVRX vs. QLEIX - Expense Ratio Comparison
BIVRX has a 2.48% expense ratio, which is higher than QLEIX's 1.30% expense ratio.
Risk-Adjusted Performance
BIVRX vs. QLEIX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invenomic Fund (BIVRX) and AQR Long-Short Equity Fund (QLEIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIVRX vs. QLEIX - Dividend Comparison
BIVRX's dividend yield for the trailing twelve months is around 21.68%, more than QLEIX's 17.66% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIVRX Invenomic Fund | 21.68% | 20.26% | 28.43% | 14.52% | 3.11% | 3.21% | 4.82% | 1.21% | 0.00% | 0.00% | 0.00% | 0.00% |
QLEIX AQR Long-Short Equity Fund | 17.66% | 20.87% | 14.15% | 0.00% | 1.57% | 0.00% | 6.03% | 9.11% | 3.01% | 4.98% | 0.89% | 8.81% |
Drawdowns
BIVRX vs. QLEIX - Drawdown Comparison
The maximum BIVRX drawdown since its inception was -25.39%, smaller than the maximum QLEIX drawdown of -39.20%. Use the drawdown chart below to compare losses from any high point for BIVRX and QLEIX. For additional features, visit the drawdowns tool.
Volatility
BIVRX vs. QLEIX - Volatility Comparison
Invenomic Fund (BIVRX) has a higher volatility of 2.96% compared to AQR Long-Short Equity Fund (QLEIX) at 2.32%. This indicates that BIVRX's price experiences larger fluctuations and is considered to be riskier than QLEIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.